Archives of Current Medical Research

Yazarlar: ["Mustafa KORKMAZ", "Melek KARAKURT ERYILMAZ", "Mehmet Zahid KOÇAK", "Aykut DEMİRKIRAN", "Murat ARAZ", "Mustafa KARAAĞAÇ", "Mehmet ARTAÇ"]

Konular:-

DOI:10.47482/acmr.1175461

Anahtar Kelimeler:Bevacizumab,Glioblastoma multiforme,HALP,Prognostic marker

Özet: Background: We aimed to investigate whether the HALP score is a prognostic marker in patients with recurrent GBM who were given bevacizumab plus irinotecan. Methods: We compared the survival of patients followed up in our clinic with the diagnosis of recurrent GBM and treated with bevacizumab plus irinotecan, according to HALP score. Results: Median PFS and OS were 4.5 (0.9-14.9) and 8 (0.9-21.3) months, respectively. The median PFS of the low HALP score group was 1.85 (1.3-3.37) months, and of the high HALP score group was 4.96 (0.9-14.9) months (p=0.03). The OS of the high HALP score group (9.63 [7.28-11.9]) was statistically higher compared with low HALP score group (2.26 [0.88-3.65]) (p<0.001). In univariate analysis HALP score was a significant prognostic factor patients with low HALP score had a poorer prognosis than high HALP score (HR: 0.063, p<0.001). The multivariate analysis showed that HALP score (p=0.003), and residual tumor (p=0.029) were significant prognostic factors. In multivariate Cox regression analysis, low HALP score was a significant poor prognostic factor for OS compared with high HALP score (HR: 0.063, p<0.001). Conclusions: We showed that the HALP score at the start of treatment is an independent prognostic factor for PFS and OS in patients with recurrent GBM treated with bevacizumab plus irinotecan. The HALP score, which can be easily calculated by routine tests before chemotherapy, can be used as a pognostic marker for bevacizumab treatment decision.

---